What is Tesamorelin?

Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH). It’s designed to mimic the effects of naturally occurring GHRH, which stimulates the pituitary gland to release growth hormone. Tesamorelin is mainly studied for how it may affect fat metabolism, body composition, and growth hormone regulation in laboratory models.

What is GHRH?

Growth hormone-releasing hormone (GHRH) is a peptide produced in the hypothalamus. It plays a key role in:

• Stimulating growth hormone (GH) release from the pituitary gland

• Supporting protein synthesis and fat metabolism

• Promoting cellular repair and regeneration

• Regulating the body’s natural circadian rhythm for GH pulses

Because native GHRH is rapidly broken down in the body, researchers have created more stable analogues like Tesamorelin to allow for extended study.

How Tesamorelin is Being Studied:

1. Increases Endogenous Growth Hormone Levels

   Tesamorelin binds to GHRH receptors on the pituitary gland, triggering a natural increase in GH secretion. In lab settings, this has allowed researchers to examine the downstream effects of elevated GH, such as changes in lipid metabolism and muscle development.

   (Reference: Falutz et al., 2010)

   
   

2. Reduces Visceral Adipose Tissue in Research Models

   One of the most studied effects of Tesamorelin is its ability to reduce visceral fat, particularly in specific research populations. In multiple trials, Tesamorelin has been associated with measurable decreases in abdominal fat without significant impact on subcutaneous fat.

   (Reference: Stanley et al., 2011)

   
   

3. Preserves Insulin Sensitivity

   Unlike some GH-related peptides that may affect glucose metabolism, Tesamorelin has been observed in some models to preserve or have minimal impact on insulin sensitivity, making it a key subject in metabolic research.

   (Reference: Guaraldi et al., 2012)

   
   

References

• Falutz, J., et al. (2010). Metabolic effects of a growth hormone–releasing factor in patients with HIV. The New England Journal of Medicine, 363(8), 716–726.

• Stanley, T.L., et al. (2011). Effects of tesamorelin on visceral fat and metabolic parameters in HIV-infected patients. Journal of Clinical Endocrinology & Metabolism, 96(9), 2738–2745.

• Guaraldi, G., et al. (2012). Tesamorelin: a growth hormone-releasing factor analogue for management of HIV-associated lipodystrophy. Drugs of Today, 48(11), 745–752.

All products sold by Direct Peptides are strictly for laboratory research purposes only. They are not intended for human or animal consumption, medical, or therapeutic use. The information provided on this website is for educational and informational purposes only.